Overview

Durvalumab Plus CV301 With Maintenance Chemotherapy in Metastatic Colorectal or Pancreatic Adenocarcinoma

Status:
Active, not recruiting

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

Summary

This is a dual arm, open label phase I/II study to evaluate the safety and clinical activity of the combination of durvalumab with CV301 in combination with maintenance chemotherapy for patients with metastatic colorectal or pancreatic cancer whose disease is stable on, or responding to 1st line therapy for metastatic disease. Patients with metastatic colorectal or pancreatic adenocarcinoma who still have an adequate performance status and normal hepatic and renal function will be eligible.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Georgetown University

Collaborators:

Bavarian Nordic
Emory University
George Mason University
Indiana University
Mayo Clinic
MedImmune LLC
National Cancer Institute (NCI)
Thomas Jefferson University

Treatments:

Bevacizumab
Capecitabine
Durvalumab